Ipsen has a local presence in six countries in Asia, including Singapore where Ipsen established an affiliate in February 2016.
Ipsen markets its products in Asia either directly through its sales force or through its local partners.
Ipsen Singapore affiliate is also the regional office for Ipsen’s operations in Asia (excluding China).
Key dates :
Ipsen Asia first opened its doors in Kuala Lumpur, Malaysia ≈ 30 years ago
Establishment of Ipsen Korea affiliate
Establishment of Representative Office in Hong Kong
1st Partnership with Teijin in Japan
Establishment of Representative Office in Vietnam
Establishment of Representative Office in Japan
Establishment of Ipsen Singapore affiliate
Establishment of Ipsen Taiwan branch
Everything we do is intended to benefit patients’ health. In Asia, we focus on our key strengths – our portfolio, our pipeline, our partnerships and our people. We strive to improve innovation to secure sustainable growth in the future. We cultivate a biotech mindset, patient- and consumer-centricity, agility and speed in our processes to benefit patients across the region.
Our bold and entrepreneurial spirit combined with the highest ethical standards is the corner stone of our organization. It is the foundation of our approach to listen, partner and work with our stakeholders. At Ipsen we are ambassadors of our company values and we live by people-empowerment to make the most appropriate and informed decisions.
Our dedication to improve the health and quality of life of our patients demands utmost ethical standards throughout our company. We ensure that all decisions are made in the best interests of patients and in compliance with all applicable laws, regulations, industry codes, Ipsen policies and the Ipsen Code of Conduct.
Our Specialty Care portfolio is composed of three key therapeutic areas – Oncology, Neuroscience and Rare Diseases where we can establish a leadership position and leverage our expertise from drug development to commercialization.
In Consumer Healthcare, we are committed to establish an autonomous, growing and sustainable business through collaborative partnerships, OTx (combined prescription and over-the-counter) commercialization model and innovative brand-stretch in the field of gastroenterology and neuroscience.